Capricor Therapeutics (NASDAQ:CAPR) Given “Hold” Rating at JonesTrading

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “hold” rating reaffirmed by investment analysts at JonesTrading in a note issued to investors on Friday,Benzinga reports.

Other research analysts also recently issued reports about the stock. Roth Capital downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price on the stock. in a research report on Monday. Oppenheimer reissued a “market perform” rating on shares of Capricor Therapeutics in a research report on Monday. HC Wainwright reaffirmed a “neutral” rating on shares of Capricor Therapeutics in a report on Monday. LADENBURG THALM/SH SH cut Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday. Finally, Alliance Global Partners downgraded Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price for the company. in a report on Tuesday. Ten equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and an average target price of $29.15.

Capricor Therapeutics Stock Down 36.2%

Shares of CAPR opened at $4.19 on Friday. The stock has a 50 day moving average price of $23.50 and a 200 day moving average price of $26.93. The company has a market capitalization of $242.64 million, a price-to-earnings ratio of -1.81 and a beta of 0.42. Capricor Therapeutics has a 52-week low of $2.96 and a 52-week high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). On average, equities analysts anticipate that Capricor Therapeutics will post -0.84 EPS for the current fiscal year.

Insider Transactions at Capricor Therapeutics

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 24,100 shares of Capricor Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $30.38, for a total value of $732,158.00. Following the transaction, the chief financial officer directly owned 11,223 shares in the company, valued at approximately $340,954.74. The trade was a 68.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 25,000 shares of company stock worth $759,158. Company insiders own 9.20% of the company’s stock.

Institutional Investors Weigh In On Capricor Therapeutics

Hedge funds have recently made changes to their positions in the business. Suvretta Capital Management LLC acquired a new position in Capricor Therapeutics in the 4th quarter valued at about $51,533,000. Tang Capital Management LLC acquired a new position in shares of Capricor Therapeutics in the fourth quarter valued at approximately $49,062,000. RA Capital Management L.P. purchased a new stake in shares of Capricor Therapeutics during the fourth quarter worth approximately $43,516,000. Darwin Global Management Ltd. acquired a new stake in shares of Capricor Therapeutics during the fourth quarter worth $23,168,000. Finally, SB Capital Management Inc purchased a new position in Capricor Therapeutics in the 4th quarter valued at $11,544,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Key Capricor Therapeutics News

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Capricor highlighted peer-reviewed The Lancet publication of HOPE-3 Phase 3 data, which the company said showed Deramiocel slowed upper-limb function decline by 54% versus placebo and demonstrated cardiac benefits. The FDA committee vote is advisory and non-binding. The Lancet Publishes HOPE-3 Data
• Neutral Sentiment: Capricor reported that the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee voted 9-3 that available evidence did not support Deramiocel’s effectiveness for DMD cardiomyopathy. The vote does not constitute a final FDA decision, but it is a significant regulatory setback for the company’s primary commercial opportunity. Capricor FDA Advisory Committee Update
• Negative Sentiment: Analysts reacted by cutting their ratings: Cantor Fitzgerald moved Capricor to “Neutral” with a $3.50 price target, while Maxim Group, Ladenburg Thalmann and Alliance Global Partners also downgraded the stock. Oppenheimer separately downgraded Capricor following the adverse FDA vote. Cantor Fitzgerald Downgrade
• Negative Sentiment: Several law firms, including Bleichmar Fonti & Auld, Frank R. Cruz, Glancy Prongay Wolke & Rotter, Rosen Law Firm and others, announced investigations or securities-fraud class actions. The firms allege Capricor may have made misleading statements about Deramiocel’s trial results and efficacy; these are allegations, not established findings. BFA Law Capricor Investigation
• Negative Sentiment: The FDA briefing documents and panel decision challenged Capricor’s interpretation of the HOPE-3 results, raising uncertainty over Deramiocel’s approval prospects, future revenue potential and the company’s valuation. Capricor Shares Fall After FDA Panel Vote

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.